GFR-话题@MedSci

#GFR#

483篇内容 | 2522人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534245, encodeId=a850153424595, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：AZD9291对EGFR-TKI获得性耐药的突NSCLC疗效显著, objectType=article, longId=35713, objectId=eb7735e1356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb7735e1356, replyNumber=0, likeNumber=84, createdTime=2014-06-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb7735e1356, moduleTitle=ASCO 2014：AZD9291对EGFR-TKI获得性耐药的突NSCLC疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb7735e1356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534246, encodeId=fff6153424635, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：陆舜谈新EGFR抑制剂对NSCLC的疗效研究, objectType=article, longId=35715, objectId=936435e15c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=936435e15c5, replyNumber=0, likeNumber=76, createdTime=2014-06-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=936435e15c5, moduleTitle=ASCO 2014：陆舜谈新EGFR抑制剂对NSCLC的疗效研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=936435e15c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534238, encodeId=685d153423803, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：韩宝惠谈第三代EGFR抑制剂对NSCLC的疗效, objectType=article, longId=35652, objectId=28ae35652b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28ae35652b4, replyNumber=0, likeNumber=68, createdTime=2014-06-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28ae35652b4, moduleTitle=ASCO 2014：韩宝惠谈第三代EGFR抑制剂对NSCLC的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28ae35652b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534237, encodeId=cd1d153423ea1, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：基于EGFR突变的新辅助治疗IIIA-N2期NSCLC可行, objectType=article, longId=35638, objectId=e9c4356382d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9c4356382d, replyNumber=0, likeNumber=59, createdTime=2014-06-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9c4356382d, moduleTitle=ASCO 2014：基于EGFR突变的新辅助治疗IIIA-N2期NSCLC可行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9c4356382d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534236, encodeId=d6101534236af, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：EGFR阳性NSCLC厄洛替尼辅助治疗DFS无获益（RADIANT研究）, objectType=article, longId=35632, objectId=e39f3563261, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e39f3563261, replyNumber=0, likeNumber=49, createdTime=2014-06-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e39f3563261, moduleTitle=ASCO 2014：EGFR阳性NSCLC厄洛替尼辅助治疗DFS无获益（RADIANT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e39f3563261)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534235, encodeId=5c1715342354b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：三项EGFR突变的NSCLC患者辅助治疗试验, objectType=article, longId=35631, objectId=a31235631c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a31235631c3, replyNumber=0, likeNumber=66, createdTime=2014-06-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a31235631c3, moduleTitle=ASCO 2014：三项EGFR突变的NSCLC患者辅助治疗试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a31235631c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534234, encodeId=95051534234d5, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Immunity：王红艳等揭示VEGFR-3抑制巨噬细胞通路的新机制, objectType=article, longId=35398, objectId=12173539877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12173539877, replyNumber=0, likeNumber=49, createdTime=2014-05-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12173539877, moduleTitle=Immunity：王红艳等揭示VEGFR-3抑制巨噬细胞通路的新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12173539877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534233, encodeId=0c16153423312, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014专家点评：mCRC一线靶向治疗抗VEGF还是抗EGFR？, objectType=article, longId=35106, objectId=224f351069b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=224f351069b, replyNumber=0, likeNumber=64, createdTime=2014-05-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=224f351069b, moduleTitle=ASCO 2014专家点评：mCRC一线靶向治疗抗VEGF还是抗EGFR？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=224f351069b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534232, encodeId=44391534232d2, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：新VEGFR抑制剂呋喹替尼治疗结直肠癌安全有效, objectType=article, longId=35093, objectId=b4ba3509361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4ba3509361, replyNumber=0, likeNumber=56, createdTime=2014-05-23, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4ba3509361, moduleTitle=ASCO 2014：新VEGFR抑制剂呋喹替尼治疗结直肠癌安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4ba3509361)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534231, encodeId=849e15342318e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO 2014：高TIMP-1水平可作为EGFR抑制疗法生物标志物, objectType=article, longId=35087, objectId=12373508e48, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12373508e48, replyNumber=0, likeNumber=77, createdTime=2014-05-23, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12373508e48, moduleTitle=ASCO 2014：高TIMP-1水平可作为EGFR抑制疗法生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12373508e48)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534230, encodeId=e15f1534230af, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果, objectType=article, longId=34270, objectId=a77a342e036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a77a342e036, replyNumber=0, likeNumber=58, createdTime=2014-05-07, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a77a342e036, moduleTitle=CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a77a342e036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534229, encodeId=393b15342291f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Immunity：VEGFR-3抑制巨噬细胞通路TLR4-NF-κB, objectType=article, longId=34197, objectId=49823419e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49823419e0d, replyNumber=0, likeNumber=42, createdTime=2014-05-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49823419e0d, moduleTitle=Immunity：VEGFR-3抑制巨噬细胞通路TLR4-NF-κB, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49823419e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534228, encodeId=78b9153422873, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Oncol：EGFR抗体西妥昔单抗可以作为结直肠癌维持治疗的优化方案（COIN-B研究）, objectType=article, longId=33906, objectId=840533906d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=840533906d2, replyNumber=0, likeNumber=90, createdTime=2014-04-30, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=840533906d2, moduleTitle=Lancet Oncol：EGFR抗体西妥昔单抗可以作为结直肠癌维持治疗的优化方案（COIN-B研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=840533906d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534227, encodeId=01e9153422e30, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JAMA：EGFR野生型非小细胞肺癌常规化疗效果更优, objectType=article, longId=33205, objectId=e625332057a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e625332057a, replyNumber=0, likeNumber=52, createdTime=2014-04-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e625332057a, moduleTitle=JAMA：EGFR野生型非小细胞肺癌常规化疗效果更优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e625332057a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534226, encodeId=bc5b153422679, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Hepatology：miR-214下调FGFR1抑制结直肠癌肝转移, objectType=article, longId=32471, objectId=a0a2324e110, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0a2324e110, replyNumber=0, likeNumber=75, createdTime=2014-03-29, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0a2324e110, moduleTitle=Hepatology：miR-214下调FGFR1抑制结直肠癌肝转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0a2324e110)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534225, encodeId=ce40153422524, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol：亚洲NSCLC患者EGFR基因突变达到50% （PIONEER研究）, objectType=article, longId=32239, objectId=e75532239d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e75532239d4, replyNumber=0, likeNumber=52, createdTime=2014-03-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e75532239d4, moduleTitle=J Thorac Oncol：亚洲NSCLC患者EGFR基因突变达到50% （PIONEER研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e75532239d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534224, encodeId=677b15342248c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Oncol：阿法替尼对亚洲EGFR突变晚期非小细胞肺癌(NSCLC)有较好的疗效（LUX-Lung 6试验）, objectType=article, longId=29593, objectId=1db929593c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1db929593c2, replyNumber=0, likeNumber=61, createdTime=2014-01-21, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1db929593c2, moduleTitle=Lancet Oncol：阿法替尼对亚洲EGFR突变晚期非小细胞肺癌(NSCLC)有较好的疗效（LUX-Lung 6试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1db929593c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534223, encodeId=7d1a153422313, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：预测非小细胞肺癌靶向治疗效果检测EGFR突变丰度很重要, objectType=article, longId=27163, objectId=bfc42e163b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfc42e163b7, replyNumber=0, likeNumber=61, createdTime=2013-11-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfc42e163b7, moduleTitle=JCO：预测非小细胞肺癌靶向治疗效果检测EGFR突变丰度很重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfc42e163b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534222, encodeId=4f031534222e2, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cancer Res：EGFR亚型 EGFRvA能增强肿瘤细胞侵袭力, objectType=article, longId=26786, objectId=3e1226e8622, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e1226e8622, replyNumber=0, likeNumber=91, createdTime=2013-11-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e1226e8622, moduleTitle=Cancer Res：EGFR亚型 EGFRvA能增强肿瘤细胞侵袭力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e1226e8622)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534221, encodeId=c9ee153422113, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=WCLC 2013：阿法替尼有效治疗EGFR突变阳性NSCLC新证据, objectType=article, longId=26281, objectId=49c8262817e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49c8262817e, replyNumber=0, likeNumber=68, createdTime=2013-11-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49c8262817e, moduleTitle=WCLC 2013：阿法替尼有效治疗EGFR突变阳性NSCLC新证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49c8262817e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：AZD9291对EGFR-TKI获得性耐药的突NSCLC疗效显著

2014-06-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：陆舜谈新EGFR抑制剂对NSCLC的疗效研究

2014-06-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：韩宝惠谈第三代EGFR抑制剂对NSCLC的疗效

2014-06-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：基于EGFR突变的新辅助治疗IIIA-N2期NSCLC可行

2014-06-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：EGFR阳性NSCLC厄洛替尼辅助治疗DFS无获益（RADIANT研究）

2014-06-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：三项EGFR突变的NSCLC患者辅助治疗试验

2014-06-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Immunity：王红艳等揭示VEGFR-3抑制巨噬细胞通路的新机制

2014-05-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014专家点评：mCRC一线靶向治疗抗VEGF还是抗EGFR？

2014-05-24

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：新VEGFR抑制剂呋喹替尼治疗结直肠癌安全有效

2014-05-23

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO 2014：高TIMP-1水平可作为EGFR抑制疗法生物标志物

2014-05-23

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果

2014-05-07

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Immunity：VEGFR-3抑制巨噬细胞通路TLR4-NF-κB

2014-05-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Oncol：EGFR抗体西妥昔单抗可以作为结直肠癌维持治疗的优化方案（COIN-B研究）

2014-04-30

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JAMA：EGFR野生型非小细胞肺癌常规化疗效果更优

2014-04-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Hepatology：miR-214下调FGFR1抑制结直肠癌肝转移

2014-03-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol：亚洲NSCLC患者EGFR基因突变达到50% （PIONEER研究）

2014-03-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Oncol：阿法替尼对亚洲EGFR突变晚期非小细胞肺癌(NSCLC)有较好的疗效（LUX-Lung 6试验）

2014-01-21

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：预测非小细胞肺癌靶向治疗效果检测EGFR突变丰度很重要

2013-11-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cancer Res：EGFR亚型 EGFRvA能增强肿瘤细胞侵袭力

2013-11-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

WCLC 2013：阿法替尼有效治疗EGFR突变阳性NSCLC新证据

2013-11-08

科室
- - 订阅+
  - 更多科室
工具
服务